Document:

Amendment Number Three to 2004 Incentive Stock Plan

 EXHIBIT 4.7 
 AMENDMENT NUMBER THREE TO 
 ROCK-TENN COMPANY 
 2004 INCENTIVE STOCK PLAN 
 Pursuant to the power reserved in § 15 of the Rock-Tenn Company 2004 Incentive Stock Plan, Rock-Tenn Company hereby amends the Plan as follows: 
 1. Section 3.1(a) of the Plan is hereby amended to read as follows: “4,100,000 shares of Stock plus”. 
 2. Section 3.4 is amended to add the following sentence to the end of such section: If the Committee pays a cash bonus to an Eligible Employee or Director pursuant to a cash bonus incentive granted
under § 9.5(a), such cash bonus paid in any calendar year to any individual shall not exceed $5,000,000. 
 3.
Section 9.5 shall be renamed “Performance Based Grants and Cash Bonus Alternatives” and paragraph (a) of such section shall be amended to read as follows: 
 (a) General. The Committee shall (where the Committee under the circumstances deems in the Company’s best interest) either
(1) make Stock Grants and Stock Unit Grants or, as an alternative to Stock Grants or Stock Unit Grants, grant cash bonus incentives to Eligible Employees subject to at least one condition related to one, or more than one, performance goal based
on the performance goals described in § 9.5(b) which seems likely to result in the Stock Grant or Stock Unit Grant or cash bonus incentive qualifying as “performance-based compensation” under § 162(m) of the Code or (2) make
Stock Grants or Stock Unit Grants or grant cash bonus incentives under such other circumstances as the Committee deems likely to result in an income tax deduction for the Company with respect to such Stock Grant or Stock Unit Grant or cash bonus
incentive. 
 4. Section 9.5(b) is amended to read as follows: 
 (b) Performance Goals. A performance goal is described in this § 9.5(b) if such goal relates to (1) the Company’s
return over capital costs or increases in return over capital costs, (2) the Company’s return on invested capital or increases in return on invested capital, (3) the Company’s operating performance or operating performance
improvement, (4) the Company’s safety record, (5) the Company’s customer satisfaction survey, (6) the Company’s total earnings or the growth in such earnings, (7) the Company’s consolidated earnings or the
growth in such earnings, (8) the Company’s earnings per share or the growth in such earnings, (9) the Company’s net earnings or income or the growth in such earnings or income, (10) the Company’s earnings before
interest expense, taxes, depreciation, amortization and other non-cash items or the growth in such earnings, (11) the Company’s earnings before interest and taxes or the growth in such earnings, (12) the Company’s consolidated
net income or the growth in such income, (13) the value or the Company’ common stock or the growth in such value, (14)

 
the Company’s stock price of the growth in such price, (15) the weight or volume of paperboard or containerboard produced or converted by the Company, (16) the Company’s
return on assets or the growth on such return, (17) the Company’s cash flow or the growth in such cash flow, (18) the Company’s total shareholder return or the growth in such return, (19) the Company’s expenses or the
reduction of such expenses, (20) the Company’s sales or sales growth; (21) the Company’s overhead ratios or changes in such ratios, (22) the Company’s expense-to-sales ratios or the changes in such ratios, or
(23) the Company’s economic value added or changes in such value added. The performance goals for the participants will (as the Committee deems appropriate) be based on criteria related to company-wide performance, division-specific or
other business unit-specific performance (where the Committee can apply the business criteria on such basis), plant or facility-specific performance, department-specific performance, personal goal performance or any combination of the
performance-based criteria. 
 5. Section 9.5(c) shall be renamed as “Alternative Goals” and is amended to read
as follows: 
 (c) Alternative Goals. A performance goal under this § 9.5 may be set in any manner determined
by the Committee, including looking to achievement on an absolute or relative basis in relation to peer groups or indexes. Further, the Committee may express any goal in alternatives, or in a range of alternatives, as the Committee deems appropriate
or helpful, such as including or excluding (1) any acquisitions or dispositions, restructurings, discontinued operations, extraordinary items, and other unusual or non-recurring charges, (2) any event either not directly related to the
operations of the Company or not within the reasonable control of the Company’s management, or (3) the effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles. 
 This Amendment Number Three shall be effective as of January 30, 2009. 
  

			
	ROCK-TENN COMPANY
		
	By:	 	/s/ Steven C. Voorhees
	Title:	 	EVP & CFO
	Date:	 	1/30/2009Pricing and Delivery Amendment

 EXHIBIT 10.1 
 CONFIDENTIAL 
 ArthroCare Corporation 

And 
 Smith & Nephew, Inc. 
 Pricing and Delivery Amendment 16 June 2008 
  

	1.	The Distribution Agreement between ArthroCare Corporation, and ArthroCare Corporation Cayman Islands (“ARTC”) and Smith & Nephew, Inc.
(“S&N”) dated September 2, 2005 (the “Agreement”) It amended as follows. Except as expressly stated in this Pricing and Delivery Amendment 16 June 2008 (“Amendment”), all other terms of the Agreement shall
remain in force. This Amendment is effective 16 June 2008 (“Effective Date”). 

  

	2.	ARTC may ship to S&N up to 50% of S&N’s current forecast for ARTC Manufactured Products (those products now scheduled for delivery between July 1,
2008 to March 31, 2009) in advance of the originally anticipated delivery dates at times of ARTC’s choosing. S&N shall accept those shipments (subject to inspection and other terms of the Agreement) in advance of the originally
anticipated delivery dates. ARTC may not under supply S&N’s forecasted amounts. All other terms of the Agreement shall remain in force and apply to all shipments and payments shall be due as if the shipments were not accelerated. Early
shipment and early acceptance shall not operate to penalize any party under the Agreement. For the first sixty (60) days of this Amendment, ARTC shall not ship early more than $1.2 million dollars worth of ARTC Manufactured Products.

  

	3.	ARTC shall give S&N at least [*] weeks advance written notice of any shipments of ARTC Manufactured Products. The notice shall include shipment quantities and
delivery date. 

  

	4.	Reference Prices charged by ARTC to S&N for ARTC Manufactured Products as of and after the Effective Date of this Amendment shall be reduced by [*] percent ( [*] %)
for products shipped early under Section 1 of this Amendment and [*] percent ([*] %) for all other ARTC Manufactured Products. 

  

	5.	For 2008 and the remainder of the term of the Agreement (including renewals), all performance-based price increases set forth in Exhibit S-D shall be [*] at [*] percent
([*] %). The parties agree to cooperate to reduce manufacturing costs. ARTC shall promptly notify S&N of any manufacturing cost reductions and the Transfer Price for ARTC Manufactured Products such reductions shall be reduced thereafter such
that the cost reductions are [*] by S&N and ARTC. 

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

	6.	The Agreement, the License Agreement and this Amendment shall be binding on S&N and ARTC, including their respective successors and assigns.

  

	7.	This Amendment may be cancelled by either party on written notice at any time within [*] days after the Effective Date of the Amendment, as set forth herein.

  

			
	For Smith & Nephew, Inc.
	
	/s/ Michael G. Frazzette
	Name	 	Michael G. Frazzette
	Title	 	President

  

									
	For ArthroCare Corporation	 		 	For ArthroCare Corporation Cayman Islands
			
	/s/ Michael A. Baker	 		 	/s/ Michael A. Baker
	Name	 	Michael A. Baker	 		 	Name	 	Michael A. Baker
	Title	 	President & CEO	 		 	Title	 	President & CEO

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.Amendment 16 Development & Supply of S&N Branded Probes

 EXHIBIT 10.2 
 CONFIDENTIAL 
 ArthroCare Corporation and
Smith & Nephew, Inc. 
 Amendment 16 June 2008 for Development and Supply of 
 S&N Branded Probes and Controllers 
 The Supply and Distribution Agreement between ArthroCare Corporation and ArthroCare Corporation Cayman Islands (“ARTC”) and Smith & Nephew, Inc. (“S&N”) dated
September 2, 2005 (the “Agreement”) is amended as follows. Except as expressly stated in the amendment, all other terms of the Agreement shall remain in force. The effective date of this Amendment 16 June 2008 for Development and
Supply of S&N Branded Probes and Controllers is 16 June 2008. 
  

	1.	ARTC and S&N shall cooperate to modify the probes listed in Schedule A attached hereto to incorporate S&N branding and different connectors from the ARTC
products. These modified probes shall be deemed Licensed OEM Products under the Agreement and the modifications shall be made under Section 2.6 of the Agreement. 

  

	2.	ARTC and S&N shall cooperate to modify the controllers and accessories listed in Schedule A attached hereto to incorporate S&N branding and different
connectors. These modified controllers shall be deemed Non-Licensed OEM Products under the Agreement and the modifications shall be made under Section 2.6 of the Agreement. 

  

	3.	ARTC will own all 510(k)s for the new products. ARTC will own OUS and OUS registrations for the new products which will carry ARTC’s CE registration. ARTC will
develop necessary documentation to secure CE Mark and other OUS registrations including labeling, manufacturing processes and validations, design documentation and testing as needed for registration purposes for the S&N branded probes and
Controllers. 

  

	4.	The probes and controllers shall be modified in two (2) phases. Phase 1 shall include the controller and the probes identified with the notation “Phase
1.” The parties shall use commercially reasonable efforts to complete the modification of the Phase 1 devices and file for FDA clearance on or before [*] and have products ready for commercialization by S&N by [*]. Phase 2 shall include the
probes identified with the notation “Phase 2.” Phase 2 modifications shall include adding [*] to the probes. The parties shall use commercially reasonable efforts to complete the Phase 2 devices and file for FDA clearance on or before [*].

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

	5.	The scope of the activities included in Phase 1 and Phase 2 are set forth in Schedule B, which is attached hereto. The total cost to S&N for modifying the
Phase 1 controllers and wands (not including transfer pricing) shall not exceed [*] with the actual cost being determined using the calculation set forth in Section 2.6 of the Agreement. The tasks to be performed by ARTC in connection with
modifying the products are set forth in Schedule B attached hereto. Upon completion of Phase 1, ARTC and S&N will assess actual Phase 1 costs to determine appropriate Phase 2 Non Recurring Expenses for Phase 2 and a new agreement for
Phase 2 costs will be negotiated in good faith. 

  

	6.	ARTC shall supply S&N with the modified products listed in Schedule A for the Transfer Prices listed in Schedule A in accordance with the other terms
of the Agreement. 

  

	7.	ARTC and S&N agree to negotiate in good faith to allow S&N to purchase refurbished controllers from ARTC that have been modified according to Paragraph 2
hereof. The Transfer Price to S&N for such refurbished controllers shall not negotiated by the parties as applicable. 

  

	8.	Through S&N, ARTC shall provide service for ARTC Manufactured Products at ARTC’s cost for such service. ARTC may provide S&N with sufficient information to
permit S&N to service the ARTC Manufactured Products itself 

  

	9.	The royalty payments of the Settlement and License Agreement between S&N and ARTC dated September 2, 2005 (the “License Agreement”) shall apply to
the Licensed OEM Products developed and supplied to S&N under this amendment. 

  

	10.	The parties agree that they will negotiate in good faith to add other ARTC products (hardware and software) to the Agreement in the future on terms, including pricing
terms, substantially similar to those contained herein. In particular, ARTC agrees that it shall make available to S&N as ARTC Manufactured Products bipolar RF wands, controllers (including activation or modification of features using software)
and accessories that are no more than one generation behind ARTC’s then newest products. For purposes of the Agreement, “ARTC’s then newest products” shall mean bipolar RF wands, controllers and accessories that ARTC’s that
are being actively marketed and sold by ARTC as its most current products limited to the field of products in Sports Medicine at that time and “no more than one generation behind ARTC’s then newest products” shall mean bipolar RF
wands, controllers and accessories that ARTC’s that (a) have been marketed or sold by ARTC as superseded, obsoleted or replaced by any newer version of an ARTC product that provides substantially similar functionality for substantially the
same use as the older product; or (b) has been actively sold and marketed as ARTC’s most current product for a period of [*]. Further, in the case of products that fall under 10(a) and (b), ARTC shall make those products available to
S&N as ARTC Manufactured Products [*] months after the products first fall under that definition. The parties shall meet at least twice per year to determine whether additional products are to be added to this Amendment.

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

  

 2 

	11.	The parties agree to work together to determine the most expedient way to supply hip and small joint RF ablation and cutting wands to S&N that are compatible with
the controllers being supplied under this Agreement. This may include converting S&N’s existing hip and small joint monopolar RF wands for use with the controllers supplied hereunder. 

  

	12.	The Agreement, the License Agreement and this Amendment shall be binding on S&N and ARTC, including their respective successors and assigns.

  

	13.	This Amendment may be cancelled by either party on written notice at any time within [*] days after the Effective Date of the Amendment, as set forth herein.

  

			
	For Smith & Nephew, Inc.
	
	/s/ Michael G. Frazzette
	Name	 	Michael G. Frazzette
	Title	 	President

  

									
	For ArthroCare Corporation	 		 	For ArthroCare Corporation Cayman Islands
			
	/s/ Michael A. Baker	 		 	/s/ Michael A. Baker
	Name	 	Michael A. Baker	 		 	Name	 	Michael A. Baker
	Title	 	President & CEO	 		 	Title	 	President & CEO

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

  

 3 

 SCHEDULE A 
 [*] 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

  

 4 

 SCHEDULE B 
 [*] 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]